### **Overview** Ipca Laboratories Ltd., established in 1949 and headquartered in Mumbai, is a fully integrated, vertically aligned pharmaceutical company with a strong global footprint. The company operates across the entire pharmaceutical value chain—from Active Pharmaceutical Ingredients (APIs) to Finished Dosage Forms (FDFs)—and derives nearly **50% of its revenue from exports**, serving over **120 countries**. It is recognized as one of the **world’s largest manufacturers** of over a dozen APIs, with regulatory approvals from stringent agencies including **US-FDA, EDQM (Europe), PMDA (Japan), and WHO-Geneva**. Key leadership includes **Premchand Godha**, Executive Chairman, guiding the company's strategic growth. --- ### **Business Model & Global Footprint** - **Vertical Integration**: End-to-end manufacturing of APIs and FDFs. - **Export-Driven**: Exports constituted ~50% of income in recent years, with key markets in **Europe, Africa, the U.S., Canada, Australia, and Latin America**. - **Diversified Portfolio**: No single product or customer contributes more than 10% of annual revenue, reducing concentration risk. - **Therapeutic Focus**: Strong presence in **pain management, rheumatology, anti-malarials, cardiology, urology, and autoimmune therapies**. Key brands like **Zerodol** lead growth in pain management. The company maintains a **globally dispersed subsidiary structure**, enhancing market access and regulatory control: - **U.S. Subsidiaries**: Ipca Pharmaceuticals, Inc., Pisgah Laboratories Inc. (liquid injectables and oral liquids plant under construction in North Carolina), and Bayshore Pharmaceuticals LLC (80%-owned, awaiting FDA clearance). - **Europe**: - **Onyx Scientific Ltd. (UK)** – FDA- and MHRA-approved facility; supports R&D and contract services. - **Unichem Ireland** – Acquired in FY2024 to serve as a European front-end for dossier holding and distribution. - **Australia & New Zealand**: - **Ipca Pharma (Australia) Pty Ltd.** manages TGA registrations. - **Ipca Pharma (NZ) Pty Ltd.** is 100%-owned and manages distribution in New Zealand. - **Africa**: **Ipca Pharma Nigeria Ltd.** is a wholly owned subsidiary supporting regional operations. - **Latin America**: Presence in **Mexico and Brazil**, with plans for consolidation. --- ### **Recent Strategic Developments (2024–2025)** #### **1. Expansion in Biosimilars** Ipca is strategically expanding into **high-growth biosimilars**, particularly **monoclonal antibodies (mAbs)** for **oncology and autoimmune diseases**, through a new **greenfield mAbs facility in Pithampur, Madhya Pradesh** (₹250 crore investment, trial production expected Q2 FY2025–26). Key Partnership: In **September 2025**, Ipca entered into a **technology transfer and joint development agreement** with **BioSimilar Sciences PR LLC (BSS)**, a Puerto Rico-based biotech firm. Under this collaboration: - A **late-stage monoclonal antibody biosimilar** will be transferred from India to BSS’s **200,000 sq. ft. biomanufacturing campus in Aguadilla, Puerto Rico**. - The biosimilar targets **autoimmune diseases and cancer** in a U.S. market **valued at over USD 4 billion**, growing at **12% annually**. - **OcyonBio Puerto Rico**, a CDMO and affiliate of BSS, will provide **aseptic fill-finish capacity of up to 60 million units/year**. - The goal: **Secure the U.S. supply chain, accelerate regulatory timelines, and enable "Made-in-America" production**. This partnership integrates: - **Ipca’s R&D and process development capabilities** - **BSS’s regulatory and commercial expertise (via its LESS strategy)** - **OcyonBio’s U.S.-based sterile manufacturing infrastructure** The alliance aims to be an **end-to-end biosimilars powerhouse**, combining Indian innovation with American manufacturing security. #### **2. Greenfield Investments (FY2025–26 Outlook)** - **Dewas, MP**: ₹275 crore investment in a **formulations manufacturing facility**; trial production expected in **Q4 FY2025–26**. - **Hingni, Maharashtra**: ₹150 crore new **bulk drugs (API) unit**, with trials in **H2 FY2025–26**. - **Pithampur, MP**: ₹250 crore **mAb biosimilars plant**, trial production in **Q2 FY2025–26**. - **Pisgah Forest, NC (USA)**: $20 million facility for **liquid injectables and oral liquids**; trials expected in **H2 FY2025–26**. These expansions are designed to **de-risk supply chains, support new product launches, and meet growing international demand**. --- ### **International Market Performance** #### **Europe** - Strong regulatory progress: **58 out of 61 generic dossiers approved in 2025**, **66 APIs with EDQM-COS certification**. - **Exports to Europe**: ₹806.11 crores in FY2024–25 (3% YoY growth). - Transitioning to **direct commercialization in the UK** under its own brand, with multiple new launches planned. - Acquired **Unichem Ireland (₹813.82 crore turnover, ₹112.40 crore post-tax profit in FY2024)** to serve as a European hub. #### **Africa** - Exports: ₹545.70 crores in FY2024–25, up 5% from prior year. - Strategy: Expanding branded business through **dedicated field force, new product registrations, and increased geographical reach**. #### **Rest of World (ROW)** - Market share grew from **1.58% to 1.86% over four years**, with expected revenue crossing **₹500 crores** and **15–17% annual growth**. - Active filings in **Latin America and emerging ROW markets**. --- ### **Innovation & Product Launches** - **Diulcus®**: A **novel topical drug for Diabetic Foot Ulcers (DFU)**, developed in partnership with **NovaLead** and funded by **BIRAC (Govt. of India)**. - **Approved by CDSCO (Aug 2024)** and launched commercially in India under an **exclusive IP licensing agreement**. - Demonstrated **20% higher efficacy** in wound closure vs. standard of care in **Phase III trials**. - Patents secured in **USA, EU, and Japan**. - **R&D Focus**: Investing in novel drug delivery systems, bioequivalence studies, and **patented process innovations**. Multiple patent filings in USA, India, and global jurisdictions. --- ### **Subsidiaries, Joint Ventures & Associates** | **Entity** | **Ownership** | **Notes** | |----------|-------------|---------| | **Unichem Laboratories Ltd.** | Fully owned | Key subsidiary; operates in U.S., Brazil, China, South Africa, Ireland. Brazilian business grew **65% YOY in H1 FY2023–24**. | | **Unichem China Pvt Ltd** | 52.67% | Controls China operations. | | **Trophic Wellness Pvt. Ltd.** | 55% (since 2021) | Nutraceuticals business; direct-to-consumer model. Generated ~₹100 crore revenue (2021), now profitable. | | **Avik Pharmaceutical Ltd.** | 50% | Joint venture; API and formulation manufacturing. | | **Lyka Labs Ltd.** | 40.98% (36.34% voting) | Associate; injectables and hospital-focused products. Integration into IPCA networks planned. | | **Krebs Biochemicals & Industries Ltd.** | 49.65% | Associate; bulk chems and intermediates. | | **CCPL Software Pvt. Ltd.** | 28.95% | IT and software services arm. | | **OcyonBio Puerto Rico** | Partner via BSS | CDMO offering microbial and mammalian drug substance and fill-finish services. Strategic for U.S. biosimilars. | --- ### **Operational & Regulatory Status** - **Regulatory Compliance**: Three plants previously had US-FDA observations; corrective actions taken. Aiming for full U.S. market re-entry in **Q1 FY2025** after import alert resolution. - **Capacity Utilization**: - Pithampur: ~30% (FDF), Devas being scaled. - Silvassa FDF plant: low utilization. - API expansion at **Ratlam** and **Dewas** improving scalability. - **Domestic Growth**: Domestic formulations grew **12% in H1 FY2023–24**; pain therapies dominate (~50% of domestic business), growing faster than market. --- ### **Challenges & Risks** - **Pricing Pressure**: Sartans (e.g., Losartan) face price erosion (down 50% in recent years), though volume share gained. - **Raw Material Inflation**: Sharp increases in **caustic soda (+150%), phosphoric acid (+235%), sulfuric acid (+88%)**, and **paracetamol (₹350 to ₹900/kg)** have impacted gross margins. - **Geopolitical Risks**: Supply disruptions in **Russia, Sri Lanka, Ukraine** affected export growth. - **Distributor Transition**: Shift from third-party to in-house distribution in **UK** led to temporary revenue disruption but is now recovering.